EXORPHIA, Inc.
Pursuing the potential of next-generation new modality and exosome medicine
Exosomes secreted from cells are generating a lot of buzz as a next-generation new modality without using cells since they efficiently deliver various cell-derived molecules to target cells. EXORPHIA has developed a unique platform technology called INPACT-EV™ that concentrates, purifies, and characterizes exosomes to a high degree of purity without rendering the exosomes inactive. Together with acquiring new animal PoC in two respiratory illnesses with bone marrow MSC-derived exosomes, new pipelines are being expanded. Through the research and development of safe and highly effective pharmaceuticals that leverage the properties of exosomes, it is hoped that this will contribute to the development of therapeutic drugs for intractable diseases for which there are still no effective treatments.
- Establishment Date
- May 2019
- Business
- Research and development, manufacturing, and sales of human cell-derived exosome pharmaceutical products
- CEO
- Koji Kuchiishi, Representative Director
KII’s Perspective
At the same time as developing proprietary platform technology, pipeline development has been carried out with the help of many research institutes, with the expectation of forming a resolute position as a pioneer of exosome drug development, generating a lot of buzz as a next-generation pharmaceutical product.
KII growth support
Financing assistance, Business strategy support, Business alliance support, Recruitment support, Public relations support, Appointment of directors
